This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Musial, J. Articles by Edmunds, L. H. Search for Related Content PubMed PubMed Citation Articles by Musial, J. Articles by Edmunds, L. H., Jr

Circulation, Vol 82, 261-273, Copyright © 1990 by American Heart Association

ARTICLES

Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms

J Musial, S Niewiarowski, B Rucinski, GJ Stewart, JJ Cook, JA Williams and LH Edmunds Jr
Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia.

Previous studies indicate that exposure of fibrinogen receptors associated with glycoprotein IIb/IIIa complex contributes to platelet loss during cardiopulmonary bypass. Recently, we isolated a number of RGD (Arg-Gly-Asp)-containing, low molecular weight, cysteine-rich peptides from viper venoms. These peptides, which we propose to call "disintegrins," block platelet-fibrinogen interaction and platelet aggregation. We compared the effect of RGDS (Arg-Gly-Asp-Ser) and four disintegrins (echistatin, flavoridin, albolabrin, and bitistatin) on platelet behavior in a membrane oxygenator. During simulated extracorporeal circulation for 2 hours, platelet count decreased to about 30% of initial values. Addition of echistatin (60-200 nM), albolabrin (60-200 nM), bitistatin (60 nM), and flavoridin (45 nM) significantly inhibited platelet loss in the circuit. RGDS (33 microM) did not show any significant inhibitory effect. ADP-induced platelet aggregation was inhibited in samples of platelet-rich plasma taken from the circuits containing disintegrins. However, echistatin appeared to be a more potent inhibitor of platelet aggregation, whereas albolabrin and flavoridin interfered more selectively with platelet loss from the circuit. Echistatin prevented the accumulation of glycoprotein IIIa on the surface of the circuit. Echistatin (60-200 nM), flavoridin (45 nM), bitistatin (60 nM), and albolabrin (200 nM) significantly inhibited the loss of beta-thromboglobulin from platelets into circulating plasma. Electron microscopy studies demonstrated shape change but not degranulation in platelets circulating in the presence of 200 nM echistatin. On the other hand, this peptide (up to 1,000 nM) did not prevent loss of alpha granules and beta-thromboglobulin from thrombin- stimulated platelets, although it prevented their aggregation. In conclusion, disintegrins protect platelets in the circuit by preventing their adhesion to surfaces and, therefore, preventing fragmentation of adhered platelets under the shear stress of flowing blood. This study indicates that disintegrins may be potential candidates for platelet protection during cardiopulmonary bypass.

This article has been cited by other articles:

				M. Buhusi, M. C. Schlatter, G. P. Demyanenko, R. Thresher, and P. F. Maness L1 Interaction with Ankyrin Regulates Mediolateral Topography in the Retinocollicular Projection J. Neurosci., January 2, 2008; 28(1): 177 - 188. [Abstract] [Full Text] [PDF]

				S. Tabata, S. Yamaguchi, H. Nagamine, S. Tomita, S. Arai, H. Takemura, and G. Watanabe Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass Eur. J. Cardiothorac. Surg., August 1, 2004; 26(2): 289 - 293. [Abstract] [Full Text] [PDF]

				R. H. Hongo, J. Ley, S. E. Dick, and R. R. Yee The effect of clopidogrel incombination with aspirin whengiven before coronary artery bypass grafting J. Am. Coll. Cardiol., July 17, 2002; 40(2): 231 - 237. [Abstract] [Full Text] [PDF]

				S. C. Silvestry and P. K. Smith Current status of cardiac surgery in the abciximab-treated patient Ann. Thorac. Surg., August 1, 2000; 70(2): S12 - 19. [Abstract] [Full Text] [PDF]

				T. Nakajima, K. Kawazoe, K. Ishibashi, Y. Kubota, T. Sasaki, H. Izumoto, and T. Nitatori Reduction of heparin dose is not beneficial to platelet function Ann. Thorac. Surg., July 1, 2000; 70(1): 186 - 190. [Abstract] [Full Text] [PDF]

				K. Iba, R. Albrechtsen, B. J. Gilpin, F. Loechel, and U. M. Wewer Cysteine-Rich Domain of Human ADAM 12 (Meltrin {alpha}) Supports Tumor Cell Adhesion Am. J. Pathol., May 1, 1999; 154(5): 1489 - 1501. [Abstract] [Full Text] [PDF]

				C. Marcinkiewicz, J. J. Calvete, M. M. Marcinkiewicz, M. Raida, S. Vijay-Kumar, Z. Huang, R. R. Lobb, and S. Niewiarowski EC3, a Novel Heterodimeric Disintegrin from Echis carinatus Venom, Inhibits alpha 4 and alpha 5 Integrins in an RGD-independent Manner J. Biol. Chem., April 30, 1999; 274(18): 12468 - 12473. [Abstract] [Full Text] [PDF]

				J.-R. Sheu, M. H. Yen, W. C. Hung, Y. M. Lee, C. H. Su, and T. F. Huang Triflavin Inhibits Platelet-Induced Vasoconstriction in De-endothelialized Aorta Arterioscler. Thromb. Vasc. Biol., December 1, 1997; 17(12): 3461 - 3468. [Abstract] [Full Text]

				Y. Hiramatsu, N. Gikakis, H. L. Anderson III, J. H. Gorman III, C. Marcinkiewicz, R. J. Gould, S. Niewiarowski, and L. H. Edmunds Jr. TIROFIBAN PROVIDES ""PLATELET ANESTHESIA"" DURING CARDIOPULMONARY BYPASS IN BABOONS J. Thorac. Cardiovasc. Surg., January 1, 1997; 113(1): 182 - 193. [Abstract] [Full Text]

				R. L. Korn, C. A. Fisher, E. R. Livingston, N. Stenach, S. J. Fishman, V. Jeevanandam, and V. P. Addonizio THE EFFECTS OF CARMEDA BIOACTIVE SURFACE ON HUMAN BLOOD COMPONENTS DURING SIMULATED EXTRACORPOREAL CIRCULATION J. Thorac. Cardiovasc. Surg., May 1, 1996; 111(5): 1073 - 1084. [Abstract] [Full Text]

				J. Lefkovits, E. F. Plow, and E. J. Topol Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine N. Engl. J. Med., June 8, 1995; 332(23): 1553 - 1559. [Full Text] [PDF]

				A. Bernabei, N. Gikakis, M. A. Kowalska, S. Niewiarowski, and L. H. Edmunds Jr Iloprost and Echistatin Protect Platelets During Simulated Extracorporeal Circulation Ann. Thorac. Surg., January 1, 1995; 59(1): 149 - 153. [Abstract] [Full Text]

				G Shankar, I Davison, M. Helfrich, W. Mason, and M. Horton Integrin receptor-mediated mobilisation of intranuclear calcium in rat osteoclasts J. Cell Sci., January 5, 1993; 105(1): 61 - 68. [Abstract] [PDF]

				C. Marcinkiewicz, Y. Taooka, Y. Yokosaki, J. J. Calvete, M. M. Marcinkiewicz, R. R. Lobb, S. Niewiarowski, and D. Sheppard Inhibitory Effects of MLDG-containing Heterodimeric Disintegrins Reveal Distinct Structural Requirements for Interaction of the Integrin alpha 9beta 1 with VCAM-1, Tenascin-C, and Osteopontin J. Biol. Chem., October 6, 2000; 275(41): 31930 - 31937. [Abstract] [Full Text] [PDF]